Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
HAHalozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO)

NASDAQ Global Select · Currency in USD
$126.86 ▲ +1.23 (+0.98%)
As of Oct 26, 1:25 PM ET. Market open.

Summary

Previous Close
$125.63
Open
$126.86
Day's Range
$126.03 – $127.77
52 Week Range
$61.23 – $127.77
Volume
423,595
Avg. Volume
2,190,436
Market Cap
$14.40B
Beta (5Y Monthly)
0.88
PE Ratio (TTM)
36.04
EPS (TTM)
$3.53
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$110.00

Profile: Halozyme Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
423
CEO
Helen I. Torley

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $2.30 · Revenue est. $490.85M
DateEst.Actual
Aug 6, 2026$1.79$2.28Beat
May 11, 2026$1.55$1.60Beat
Feb 17, 2026$2.15-$0.24Miss
Nov 3, 2025$1.63$1.72Beat
Aug 5, 2025$1.23$1.54Beat
May 6, 2025$0.95$1.11Beat

Analyst view

Consensus price target
$110.00 ▼ -13.3%
Range $90.00 – $130.00
Rating: Buy
Buy 67% · Hold 30% · Sell 4%

Similar stocks

Get free alerts on HALO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.